Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus AC adjuvant chemotherapy for postoperative breast cancer
ChiCTR1900022560Phase 4Not yet recruiting
- Sponsor
- Three Gorges Hospital of Chongqing University
- Start
- May 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nab-paclitaxel and cyclophosphamide in breast cancer, sponsored by Three Gorges Hospital of Chongqing University. Primary endpoint: Relapse-free survival. Planned start May 2019; status: not yet recruiting.
02
Drugs
nab-paclitaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900022560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022560.